Identification and management of alcohol withdrawal syndrome.

Antonio Gasbarrini, Giovanni Addolorato, Antonio Mirijello, Cristina D'Angelo, Anna Ferrulli, Gabriele Angelo Vassallo, Mariangela Antonelli, Lorenzo Leggio, Fabio Caputo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

66 Citazioni (Scopus)

Abstract

Symptoms of alcohol withdrawal syndrome (AWS) may develop within 6-24 h after the abrupt discontinuation or decrease of alcohol consumption. Symptoms can vary from autonomic hyperactivity and agitation to delirium tremens. The gold-standard treatment for AWS is with benzodiazepines (BZDs). Among the BZDs, different agents (i.e., long-acting or short-acting) and different regimens (front-loading, fixed-dose or symptom-triggered) may be chosen on the basis of patient characteristics. Severe withdrawal could require ICU admission and the use of barbiturates or propofol. Other drugs, such as α2-agonists (clonidine and dexmetedomidine) and β-blockers can be used as adjunctive treatments to control neuroautonomic hyperactivity. Furthermore, neuroleptic agents can help control hallucinations. Finally, other medications for the treatment for AWS have been investigated with promising results. These include carbamazepine, valproate, sodium oxybate, baclofen, gabapentin and topiramate. The usefulness of these agents are discussed.
Lingua originaleEnglish
pagine (da-a)353-365
Numero di pagine13
RivistaDrugs
Stato di pubblicazionePubblicato - 2015

Keywords

  • Alcohol withdrawal syndrome

Fingerprint

Entra nei temi di ricerca di 'Identification and management of alcohol withdrawal syndrome.'. Insieme formano una fingerprint unica.

Cita questo